Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III
Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...
EUR/JPY Price Forecast: Key downside target emerges near 160.00
The EUR/JPY cross gains momentum to around 160.75, snapping the two-day losing streak during the early European session on ...
ECB Holds Rates Steady as German Data Weakens: EUR/USD and EURO STOXX 50 Outlook
EUR/USD struggles as ECB holds rates at 2.90%, while weak German data fuels growth concerns. Will the euro rebound or slide ...
GlobalData on MSN17h
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Altcoins LINK, AVAX and LTC Price Prediction: Double-digit gains ahead
However, the RSI reads 44 and points upwards. For the bullish momentum to sustain, the RSI must close above the neutral level ...
Business Wire3h
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...
Japanese Yen and Aussie Dollar News: BoJ vs. Fed Rate Path Battle Heats Up
Japan’s retail sales and job data fuel BoJ rate hike bets, pressuring USD/JPY. Fed’s inflation stance also in focus. Will USD ...
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
BioWorld10h
Stereotaxis begins anew with Genesisx launch in EU
Continuing a cascade of positive news for Stereotaxis Inc., the company reported the first order for its petite Genesisx robot in Europe. The system received CE mark in August, but management held off ...